Search Results - "Russano, Marco"

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples by Russano, Marco, Napolitano, Andrea, Ribelli, Giulia, Iuliani, Michele, Simonetti, Sonia, Citarella, Fabrizio, Pantano, Francesco, Dell'Aquila, Emanuela, Anesi, Cecilia, Silvestris, Nicola, Argentiero, Antonella, Solimando, Antonio Giovanni, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele

“…In a large number of cancer types, treatment selection depends on the presence of specific tumor biomarkers. Due to the dynamic nature of cancer, very often…”
Get full text

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events by Cortellini, Alessio, Bersanelli, Melissa, Santini, Daniele, Buti, Sebastiano, Tiseo, Marcello, Cannita, Katia, Perrone, Fabiana, Giusti, Raffaele, De Tursi, Michele, Zoratto, Federica, Marconcini, Riccardo, Russano, Marco, Zeppola, Tea, Anesi, Cecilia, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Tudini, Marianna, Silva, Rosa Rita, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Migliorino, Maria Rita, Mallardo, Domenico, Vanella, Vito, Mosillo, Claudia, Bracarda, Sergio, Rinaldi, Silvia, Berardi, Rossana, Natoli, Clara, Ficorella, Corrado, Porzio, Giampiero, Ascierto, Paolo A.

“…Several studies have found an association between higher body mass index (BMI) and improved clinical outcomes in cancer patients receiving programmed cell…”
Get full text

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable by Cortellini, Alessio, Bersanelli, Melissa, Buti, Sebastiano, Cannita, Katia, Santini, Daniele, Perrone, Fabiana, Giusti, Raffaele, Tiseo, Marcello, Michiara, Maria, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Marconcini, Riccardo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Antonini Cappellini, Gian Carlo, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Chiari, Rita, Ricciuti, Biagio, De Giglio, Andrea, Iacono, Daniela, Gelibter, Alain, Occhipinti, Mario Alberto, Parisi, Alessandro, Porzio, Giampiero, Fargnoli, Maria Concetta, Ascierto, Paolo Antonio, Ficorella, Corrado, Natoli, Clara

“…Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. We conducted a…”
Get full text

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients by Cortellini, Alessio, Chiari, Rita, Ricciuti, Biagio, Metro, Giulio, Perrone, Fabiana, Tiseo, Marcello, Bersanelli, Melissa, Bordi, Paola, Santini, Daniele, Giusti, Raffaele, Grassadonia, Antonino, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Garufi, Carlo, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Porzio, Giampiero, Cannita, Katia, Ficorella, Corrado, Buti, Sebastiano

“…Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in…”
Get full text

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice by Cortellini, Alessio, Tucci, Marco, Adamo, Vincenzo, Stucci, Luigia Stefania, Russo, Alessandro, Tanda, Enrica Teresa, Spagnolo, Francesco, Rastelli, Francesca, Bisonni, Renato, Santini, Daniele, Russano, Marco, Anesi, Cecilia, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Occhipinti, Mario Alberto, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Bareggi, Claudia, Nigro, Olga, Tuzi, Alessandro, De Tursi, Michele, Petragnani, Nicola, Pala, Laura, Bracarda, Sergio, Macrini, Serena, Inno, Alessandro, Zoratto, Federica, Veltri, Enzo, Di Cocco, Barbara, Mallardo, Domenico, Vitale, Maria Grazia, Pinato, David James, Porzio, Giampiero, Ficorella, Corrado, Ascierto, Paolo Antonio

“…BackgroundConcomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint…”
Get full text

Prognostic and predictive factors in pancreatic cancer by Dell'Aquila, Emanuela, Fulgenzi, Claudia Angela Maria, Minelli, Alessandro, Citarella, Fabrizio, Stellato, Marco, Pantano, Francesco, Russano, Marco, Cursano, Maria Concetta, Napolitano, Andrea, Zeppola, Tea, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele

“…Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery…”
Get full text

Immunotherapy for colorectal cancer: where are we heading? by Basile, Debora, Garattini, Silvio Ken, Bonotto, Marta, Ongaro, Elena, Casagrande, Mariaelena, Cattaneo, Monica, Fanotto, Valentina, De Carlo, Elisa, Loupakis, Fotios, Urbano, Federica, Negri, Francesca V, Pella, Nicoletta, Russano, Marco, Brunetti, Oronzo, Scartozzi, Mario, Santini, Daniele, Silvestris, Nicola, Casadei Gardini, Andrea, Puzzoni, Marco, Calvetti, Lorenzo, Cardarelli, Nadia, Aprile, Giuseppe

“…In the last few years, significant advances in molecular biology have provided new therapeutic options for colorectal cancer (CRC). The development of new…”
Get more information

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases by Santini, Daniele, Barni, Sandro, Intagliata, Salvatore, Falcone, Alfredo, Ferraù, Francesco, Galetta, Domenico, Moscetti, Luca, La Verde, Nicla, Ibrahim, Toni, Petrelli, Fausto, Vasile, Enrico, Ginocchi, Laura, Ottaviani, Davide, Longo, Flavia, Ortega, Cinzia, Russo, Antonio, Badalamenti, Giuseppe, Collovà, Elena, Lanzetta, Gaetano, Mansueto, Giovanni, Adamo, Vincenzo, De Marinis, Filippo, Satolli, Maria Antonietta, Cantile, Flavia, Mancuso, Andrea, Tanca, Francesca Maria, Addeo, Raffaele, Russano, Marco, Sterpi, Michelle, Pantano, Francesco, Vincenzi, Bruno, Tonini, Giuseppe

“…We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on…”
Get full text

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes by Cortellini, Alessio, Friedlaender, Alex, Banna, Giuseppe L., Porzio, Giampiero, Bersanelli, Melissa, Cappuzzo, Federico, Aerts, Joachim G.J.V., Giusti, Raffaele, Bria, Emilio, Cortinovis, Diego, Grossi, Francesco, Migliorino, Maria R., Galetta, Domenico, Passiglia, Francesco, Berardi, Rossana, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Tuzi, Alessandro, Gelibter, Alain, Marchetti, Paolo, Macerelli, Marianna, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Santoni, Matteo, Tudini, Marianna, Ghidini, Michele, Filetti, Marco, Catino, Annamaria, Pizzutilo, Pamela, Sala, Luca, Occhipinti, Mario Alberto, Citarella, Fabrizio, Russano, Marco, Torniai, Mariangela, Cantini, Luca, Follador, Alessandro, Sforza, Vincenzo, Nigro, Olga, Ferrara, Miriam G., D’Argento, Ettore, Leonetti, Alessandro, Pettoruti, Linda, Antonuzzo, Lorenzo, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Baldessari, Cinzia, Bertolini, Federica, Della Gravara, Luigi, Dal Bello, Maria Giovanna, Belderbos, Robert A., De Filippis, Marco, Cecchi, Cristina, Ricciardi, Serena, Donisi, Clelia, De Toma, Alessandro, Proto, Claudia, Addeo, Alfredo, Cantale, Ornella, Ricciuti, Biagio, Genova, Carlo, Morabito, Alessandro, Santini, Daniele, Ficorella, Corrado, Cannita, Katia

“…The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting…”
Get full text

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study by Cortellini, Alessio, Cannita, Katia, Tiseo, Marcello, Cortinovis, Diego L., Aerts, Joachim G.J.V., Baldessari, Cinzia, Giusti, Raffaele, Ferrara, Miriam G., D'Argento, Ettore, Grossi, Francesco, Guida, Annalisa, Berardi, Rossana, Morabito, Alessandro, Genova, Carlo, Antonuzzo, Lorenzo, Mazzoni, Francesca, De Toma, Alessandro, Signorelli, Diego, Gelibter, Alain, Targato, Giada, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Gori, Stefania, De Tursi, Michele, Mansueto, Giovanni, Zoratto, Federica, Filetti, Marco, Bracarda, Sergio, Citarella, Fabrizio, Russano, Marco, Cantini, Luca, Nigro, Olga, Buti, Sebastiano, Minuti, Gabriele, Landi, Lorenza, Ricciardi, Serena, Migliorino, Maria R., Natalizio, Salvatore, Simona, Carnio, De Filippis, Marco, Metro, Giulio, Adamo, Vincenzo, Russo, Alessandro, Spinelli, Gian P., Di Maio, Massimo, Banna, Giuseppe L., Friedlaender, Alex, Addeo, Alfredo, Pinato, David J., Ficorella, Corrado, Porzio, Giampiero

“…Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression…”
Get full text

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib by Manca, Paolo, Russano, Marco, Pantano, Francesco, Tonini, Giuseppe, Santini, Daniele

“…We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through…”
Get full text

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers by Russano, Marco, La Cava, Giulia, Cortellini, Alessio, Citarella, Fabrizio, Galletti, Alessandro, Di Fazio, Giuseppina Rita, Santo, Valentina, Brunetti, Leonardo, Vendittelli, Alessia, Fioroni, Iacopo, Pantano, Francesco, Tonini, Giuseppe, Vincenzi, Bruno

“…Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have…”
Get full text

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) by Iuliani, Michele, Simonetti, Sonia, Cristofani, Leonardo, Cavaliere, Silvia, Cortellini, Alessio, Russano, Marco, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele, Pantano, Francesco

“…BackgroundReceptor activator of nuclear factor kappa-B ligand (RANKL) can directly promote tumor growth and indirectly support tumor immune evasion by altering…”
Get full text

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations by Citarella, Fabrizio, Russano, Marco, Perrone, Giuseppe, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele

“…The genetic landscape of nonsquamous non‐small cell lung cancer (NSCLC) includes specific mutations involving primarily epidermal growth factor receptor…”
Get full text

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis by Grande, Roberta, Natoli, Clara, Ciancola, Fabrizio, Gemma, Donatello, Pellegrino, Arianna, Pavese, Ida, Garufi, Carlo, Di Lauro, Luigi, Corsi, Domenico, Signorelli, Diego, Sperduti, Isabella, Cortese, Giada, Risi, Emanuela, Morano, Federica, Sergi, Domenico, Signorelli, Carlo, Ruggeri, Enzo Maria, Zampa, Germano, Russano, Marco, Gamucci, Teresa

“…Colorectal cancer patients have a median age of incidence >65years although they are largely under-represented in phase-III trials. This large population…”
Get full text

Cabozantinib and apixaban: an hitherto unreported interaction by Santini, Daniele, Citarella, Fabrizio, Vincenzi, Bruno, Russano, Marco, Tonini, Giuseppe, Stellato, Marco

“…The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year…”
Get full text

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples by Russano, Marco, Napolitano, Andrea, Ribelli, Giulia, Iuliani, Michele, Simonetti, Sonia, Citarella, Fabrizio, Pantano, Francesco, Dell'Aquila, Emanuela, Anesi, Cecilia, Silvestris, Nicola, Argentiero, Antonella, Solimando, Antonio Giovanni, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele

“…An amendment to this paper has been published and can be accessed via the original article…”
Get full text

Steroid-refractory immune related hepatitis may hide viral re-activation by Citarella, Fabrizio, Galletti, Alessandro, Russano, Marco, Gallo, Paolo, Vespasiani-Gentilucci, Umberto, Picardi, Antonio, Tonini, Giuseppe, Vincenzi, Bruno, Santini, Daniele

“…Cancer immunotherapy has become a stronghold in modern oncology. Immune checkpoint inhibitors, in particular anti-PD-1 and anti-PD-L1 antibodies, are approved…”
Get full text

"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study by Pezzuto, Aldo, Stumbo, Luciano, Russano, Marco, Crucitti, Pierfilippo, Scarlata, Simone, Caricato, Marco, Tonini, Giuseppe

“…Erlotinib is a validated drug "for the treatment of patients affected by advanced unresectable non small cell lung cancer (NSCLC) with EGFR mutations". We want…”
Get more information

Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib. by Russano, Marco

“…Advances in cancer biology research led to the identification of new molecular drivers in non-small cell lung cancer. These alterations should be searched…”
Get more information